Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment

Aim Although suvorexant and lemborexant, which have orexin receptor antagonist activity, are used as sleep medications in Japan, no report has directly compared their efficacy safety. This study the safety of drugs. Methods retrospective cohort included patients who presented to Outpatient Department Psychiatry at Tottori University Hospital between December 1, 2020, 31, 2021. Information was obtained from 108 were newly treated with or lemborexant. Data analyzed after excluding one case discontinuation due a post-administration allergic reaction. Improvement status administration assessed retrospectively medical records by using Clinical Global Impressions-Improvement (CGI-I) Scale, is subscale Impressions (CGI) Scale. The incidence side-effects patient's first visit administration. Results There significant difference CGI-I scores (mean [SD], 3.05 [0.93]) lemborexant groups 3.38 [0.83]) (p = 0.10). continued treatment not significantly different group (12.5%) (2.9%) Patients switched had ≤4, observed switching Conclusion effectiveness However, might cause less frequently than suvorexant, least early stages treatment.